Author: PharmaSignal News Desk

Arrowhead FDA approval for Redemplo marks its transition to a commercial-stage company, targeting a rare genetic disorder.

WuXi AppTec revenue growth highlights its resilience as US sales increase by 31.9% amid easing restrictions.

Penicillin-G plant in Andhra Pradesh, with a capacity of 15,000 tonnes annually, inaugurated by PM Modi on 10 September 2025.

Roche giredestrant study demonstrates significant benefits in early breast cancer, marking a milestone with its oral SERD in the adjuvant setting.

Pfizer Metsera deal finalizes at $10 billion, enhancing Pfizer’s pipeline and market position.

Ozempic pricing is under scrutiny as Senator Sanders suggests generic versions could cost under $100/month.

Strand Therapeutics promotes Prashant Nambiar to Chief Scientific Officer, enhancing leadership with his prior experience as Senior Vice President.

Zymeworks royalty-driven model aims to create consistent shareholder value following promising cancer drug data.

Merck Winrevair heart study demonstrates significant improvement in blood flow for heart failure patients.

Alkermes bidding war with Lundbeck over a sleepiness drug could impact its market strategy and financial outlook.